Facts and figures
||June 1, 2017
||May 31, 2021
||European Institute for Biomedical Imaging Research (EIBIR), Austria
||33 partners - major universities, research institutes and clinical partners from 14 countries
The evolution of medical science and the growing pace of innovation and deployment of medical technology have led to a situation where most of the artificial ionising radiation exposure of the European population is created by diagnostic imaging or radiotherapy procedures.
The use of ionising radiation in medicine has been steadily increasing, and this trend is set to continue, with obvious health benefits for the population thanks to improved diagnostic and therapy technologies. However, the increasing use of new modalities both for diagnosis and treatment also raises a number of issues in radiological protection of patients and medical workers, as the population’s average medical exposure levels are continually rising.
Although most of these exposures result in low to moderate doses in most tissues, there is a need to evaluate the health effects of these exposures, optimise practices to reduce doses and develop dose evaluation tools that can be used in clinical practice to ensure adequate and improved radiation protection of patients and medical personnel. Whilst patient RP has been a constant concern of physicians, and regulated by the competent authorities, some specific scientific questions arise in this context, which RP research has not addressed before, at least successfully.
MEDIRAD aims to enhance the scientific bases and clinical practice of radiation protection in the medical field and thereby addresses the need to better understand and evaluate the health effects of low-dose ionising radiation exposure from diagnostic and therapeutic imaging and from off-target effects in radiotherapy.
This will be achieved by focusing on three major operational objectives:
The expected impacts of the MEDIRAD Project are briefly described in the following.